Integrity BMS    

Log In

Forgot Your Password?

Not a member? Click here!

FDA Clears ReFlow Medical’s Spex Shapeable Support Catheter
Bivalirudin in AMI: First Presentation of the Multicenter BIAMI HORIZONS
Mild Hypothermia Combined with Emergent PCI for Resuscitated Victims of Cardiac Arrest
Near-infrared Spectroscopy System for Detection of Lipid Core Containing Plaques of Interest
Understanding and Applying the new AHA/ACC Secondary Prevention Guidelines



SYMPLICITY HTN-3 Stands the Test of Time

The SIMPLICITY HTN-3 study confirmed the safety but not the efficacy of renal denervation for resistant hypertension at 6-month follow-up. Twelve-month follow-up data have continued to show that renal denervation has had no impact upon 24-hour systolic blood pressure.

For more, click here




CABG Remains the Gold Standard in Multivessel Disease

Comparative data for second generation DES and CABG in the treatment of multivessel CAD are lacking. A randomized study of everolimus-eluting stents versus CABG in 1776 patients with multivessel CAD has indicated that CABG is associated with a lower rate of the composite of death, MI, or target vessel revascularization.

For more, click here





Stents in the Cranial Circulation

Stents in the coronary circulation have revolutionized the treatment of obstructive coronary artery disease. The VISSIT randomized study examined the safety and efficacy of a balloon-expandable stent in patients with symptomatic intracranial stenosis. In this study, as compared to medical therapy, stenting was associated with increased 12-month risk of stroke or transient ischemic attack (TIA) in the same territory and increased 30-day risk of any stroke or TIA.

For more, click here




Antibiotic Therapy for Infective Endocarditis

Routine antibiotic prophylaxis for the prevention of infective endocarditis (IE) has largely been discouraged by national and international guidelines. A study of changes in the prescription of antibiotic prophylaxis and the incidence of IE in England has indicated that although prescriptions have fallen since the instruction of such guidelines, the incidence of IE has significantly increased. The increase was observed for both individuals at high and low risk of IE.

For more, click here



Strokes in TAVR Is it a Deal Breaker?
- Samir Kapadia, MD
CoreValve US Pivotal Trial
- John V. Conte, MD
Myocardial infarction with no obstructive coronary atherosclerosis
- Giampaolo Niccoli, MD, PhD
Incidence, Predictors, and Prognostic Impact of Late Bleeding (≥30 days) Complications after Transcatheter Aortic Valve Replacement (TAVR)
- Philippe Généreux, MD
Minimizing Femoral Artery Access Complications during PCI
- Michael S. Lee, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD
 Click here to visit the WEBEX archives

Impact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression.
R Puri, et al.
JACC 2015; 65:1273-1282
Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy: The TNT Trial.
Y Byun, et al.
JACC 2015; 65:1286-1295
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
G Giustino, et al.
JACC 2015; 65:1298-1310
12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension: The SYMPLICITY HTN-3 Trial.
G Bakris, et al.
JACC 2015; 65:1314-1321
Transcatheter Aortic Valve Implantation in the United Kingdom: Temporal Trends, Predictors of Outcome, and 6-Year Follow-Up: A Report From the UK Transcatheter Aortic Valve Implantation (TAVI) Registry, 2007 to 2012.
P Ludman, et al.
Circ 2015; 131:1181-1190
Temporal Trends in Revascularization Strategy and Outcomes in Left Main Coronary Artery Stenosis: Data From the Asan Medical Center-Left Main Revascularization Registry.
S Park, et al.
Circ Cardiovasc Interv 2015; 8:e001846
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease.
S Park, et al.
NEJM 2015; 372:1204-1212
Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease.
S Bangalore, et al.
NEJM 2015; 372:1213-1222
Effect of a Balloon-Expandable Intracranial Stent vs. Medical Therapy on Risk of Stroke in Patients With Symptomatic Intracranial Stenosis: The VISSIT Randomized Clinical Trial.
O Zaidat, et al.
JAMA 2015; 313:1240-1248
Incidence of Infective Endocarditis in England, 2000–13: A Secular Trend, Interrupted Time-Series Analysis.
M Dayer, et al.
The Lancet 2015; 385:1219-1228
Meta-Analysis of Multivessel Versus Culprit-Only Percutaneous Coronary Intervention in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome and Multivessel Coronary Disease.
J Jang, et al.
AJC 2015; 115:1027-1032
Prevalence and Impact of Pulmonary Hypertension on Patients With Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement.
I Barbash, et al.
AJC 2015 Online

Poll Archives
CoreValve US Pivotal Trial - Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting
John V. Conte, M.D.
Alexandra Lansky, M.D.
The REGULATE-PCI Randomized Clinical Trial
Roxana Mehran, M.D.
Marc S. Sabatine, M.D., M.P.H.
Promise Trial
Pamela S. Douglas, M.D.
CoreValve US Pivotal Trial - 2-Year Outcomes
Michael J Reardon, M.D., F.A.C.C.
Sanjit Jolly, M.D.
Rajeev K. Pathak, M.D.
(PROMISE) Trial: Economic Outcomes
Daniel B. Mark, M.D., M.P.H.
Drug-Resistant Hypertension in an Asian Population
Byeong-Keuk Kim, M.D.
Reduced Blood Pressure Lowering Effect of Catheter-Based Renal Denervation in Patients with Isolated Systolic Hypertension: Data from Pooled SYMPLICITY HTN Trials
Felix Mahfoud, M.D.
BEST Trial
Seung-Jung Park, M.D., PhD
Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.
Paul Sorajja, M.D.
Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients
Susheel Kodali, M.D.
M. Valgimigli, M.D., PhD
C. Michael Gibson, M.S., M.D.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial
Michael J. Mack, M.D.
Relation Between Frailty and Outcomes After Transcatheter Aortic Valve Replacement
Philip Green, M.D.
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Marc S. Sabatine, M.D., M.P.H.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD

First Commercial Procedures in the United States Performed With Boston Scientific’s Watchman Device

The Medicines Company’s Cangrelor Approved in Europe

New Indication Allows Brilinta to Be Crushed for Patients With Difficulty Swallowing

Medtronic’s CoreValve TAVR System Approved in Japan

FDA Approves Valve-in-Valve Procedures With CoreValve TAVR System

Medtronic CoreValve® System Receives FDA Approval for Transcatheter Valve-In-Valve Procedures


Infraredx Launches Advanced TVC Imaging System and TVC Muller Extended Bandwidth NIRS-IVUS Catheter

Medtronic Initiates Pivotal Studies of Resolute Onyx(TM) Drug-Eluting Stent in United States

Toshiba’s Infinix 4DCT Receives FDA Clearance with Aquilion PRIME CT Configuration

Boston Scientific Announces Definitive Agreement To Acquire American Medical Systems' Urology Portfolio For Up To $1.65 Billion

Penumbra Launches POD Embolization Anchoring Device at SIR

Boston Scientific to Acquire American Medical Systems’ Urology Portfolio

ArtVentive Introduces EOS Device in the United States

Vascutek to Distribute Vascular Flow Technologies’ Spiral Flow Grafts in Europe

Cardinal Health to Acquire Cordis

FDA Approves Medtronic’s In.Pact Admiral DCB to Treat SFA and Popliteal Artery Disease

Teleflex Awarded Dialysis Agreement With Premier

ArtVentive Medical’s EOS Device Receives FDA Clearance

Merit Medical’s One Snare System Cleared by FDA

FDA Clears ReFlow Medical’s Spex Shapeable Support Catheter

Philips to Acquire Volcano

TeraRecon Announces AnyOne Upgrade Program
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2015 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2015, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb